false2022-03-312022Q10001612042--12-31As of March 31, 2022, a total of 7,060,788 warrants outstanding, each carrying the right to subscribe for one ordinary share, and 575,000 senior convertible notes which can potentially be converted into 3,456,785 ordinary shares, can potentially dilute earnings per share in the future but have not been included in the calculation of diluted earnings per share because they are antidilutive for the periods presented. Similarly, a total of 6,109,942 warrants outstanding as of March 31, 2021, are also considered antidilutive for the periods presented and have not been included in the calculation. The weighted average number of shares takes into account the weighted average effect of changes in treasury shares during the year. 0001612042 2021-01-01 2021-03-31 0001612042 2022-01-01 2022-03-31 0001612042 2022-03-31 0001612042 2021-12-31 0001612042 2021-01-01 2021-12-31 0001612042 2021-08-25 2021-08-25 0001612042 2020-12-31 0001612042 2021-03-31 0001612042 ifrs-full:OrdinarySharesMember 2022-01-01 2022-03-31 0001612042 asnd:ConvertibleSeniorNotesMember 2022-01-01 2022-03-31 0001612042 asnd:Warrant1Member 2022-01-01 2022-03-31 0001612042 asnd:Warrant1Member 2022-01-01 2022-03-31 0001612042 ifrs-full:RetainedEarningsMember 2022-01-01 2022-03-31 0001612042 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-01-01 2022-03-31 0001612042 ifrs-full:ReserveOfSharebasedPaymentsMember 2022-01-01 2022-03-31 0001612042 ifrs-full:TreasurySharesMember 2022-01-01 2022-03-31 0001612042 ifrs-full:SharePremiumMember 2022-01-01 2022-03-31 0001612042 ifrs-full:IssuedCapitalMember 2022-01-01 2022-03-31 0001612042 srt:EuropeMember 2022-01-01 2022-03-31 0001612042 country:CN 2022-01-01 2022-03-31 0001612042 srt:NorthAmericaMember 2022-01-01 2022-03-31 0001612042 ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2022-01-01 2022-03-31 0001612042 ifrs-full:GoodsOrServicesTransferredOverTimeMember 2022-01-01 2022-03-31 0001612042 asnd:CollaborationPartnersAndLicenseAgreementsMember 2022-01-01 2022-03-31 0001612042 asnd:CommercialCustomersMember 2022-01-01 2022-03-31 0001612042 asnd:VisenPharmaceuticalsMember 2022-01-01 2022-03-31 0001612042 ifrs-full:LiquidityRiskMember 2022-01-01 2022-03-31 0001612042 asnd:CollaborationPartnersAndLicenseAgreementsMember 2022-01-01 2022-03-31 0001612042 asnd:RestrictedStockUnitsMember 2022-01-01 2022-03-31 0001612042 asnd:RestrictedStockUnitsMember asnd:DecemberTwoThousandAndTwentyTwoMember 2022-01-01 2022-03-31 0001612042 asnd:RestrictedStockUnitsMember asnd:DecemberTwoThousandAndTwentyThreeMember 2022-01-01 2022-03-31 0001612042 asnd:RestrictedStockUnitsMember asnd:DecemberTwoThousandAndTwentyFourMember 2022-01-01 2022-03-31 0001612042 asnd:ConvertibleSeniorNotesMember 2022-01-01 2022-03-31 0001612042 asnd:ForeignCurrencyConversionOptionMember 2022-01-01 2022-03-31 0001612042 ifrs-full:DerivativesMember asnd:SharePriceMeasurementInputMember 2022-01-01 2022-03-31 0001612042 asnd:AmericanDepositorySharesMember asnd:ConvertibleSeniorNotesMember 2022-01-01 2022-03-31 0001612042 asnd:ProfitLossMember 2022-01-01 2022-03-31 0001612042 asnd:Warrant1Member 2021-01-01 2021-03-31 0001612042 ifrs-full:RetainedEarningsMember 2021-01-01 2021-03-31 0001612042 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-01-01 2021-03-31 0001612042 ifrs-full:TreasurySharesMember 2021-01-01 2021-03-31 0001612042 ifrs-full:ReserveOfSharebasedPaymentsMember 2021-01-01 2021-03-31 0001612042 ifrs-full:SharePremiumMember 2021-01-01 2021-03-31 0001612042 ifrs-full:IssuedCapitalMember 2021-01-01 2021-03-31 0001612042 country:CN 2021-01-01 2021-03-31 0001612042 srt:NorthAmericaMember 2021-01-01 2021-03-31 0001612042 srt:EuropeMember 2021-01-01 2021-03-31 0001612042 ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2021-01-01 2021-03-31 0001612042 ifrs-full:GoodsOrServicesTransferredOverTimeMember 2021-01-01 2021-03-31 0001612042 asnd:CollaborationPartnersAndLicenseAgreementsMember 2021-01-01 2021-03-31 0001612042 asnd:CommercialCustomersMember 2021-01-01 2021-03-31 0001612042 asnd:CollaborationPartnersAndLicenseAgreementsMember 2021-01-01 2021-03-31 0001612042 asnd:ProfitLossMember 2021-01-01 2021-03-31 0001612042 asnd:Warrant1Member 2022-03-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember 2022-03-31 0001612042 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember 2022-03-31 0001612042 ifrs-full:NotLaterThanOneYearMember 2022-03-31 0001612042 ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember 2022-03-31 0001612042 ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember 2022-03-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:UsGovernmentBondsMember 2022-03-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:UsGovernmentBondsMember 2022-03-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:CommercialPapersMember 2022-03-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:CommercialPapersMember 2022-03-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:CorporateBondsMember 2022-03-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:CorporateBondsMember 2022-03-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:AgencyBondsMember 2022-03-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:AgencyBondsMember 2022-03-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember 2022-03-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember 2022-03-31 0001612042 ifrs-full:FixedInterestRateMember ifrs-full:FinancialAssetsAtAmortisedCostMember 2022-03-31 0001612042 ifrs-full:FixedInterestRateMember ifrs-full:FinancialAssetsAtFairValueMember 2022-03-31 0001612042 ifrs-full:FloatingInterestRateMember ifrs-full:FinancialAssetsAtAmortisedCostMember 2022-03-31 0001612042 ifrs-full:FloatingInterestRateMember ifrs-full:FinancialAssetsAtFairValueMember 2022-03-31 0001612042 asnd:ZeroCouponMember ifrs-full:FinancialAssetsAtAmortisedCostMember 2022-03-31 0001612042 asnd:ZeroCouponMember ifrs-full:FinancialAssetsAtFairValueMember 2022-03-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:HighGradeMember 2022-03-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:HighGradeMember 2022-03-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:UpperMediumGradeMember 2022-03-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:UpperMediumGradeMember 2022-03-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:LowerMediumGradeMember 2022-03-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:LowerMediumGradeMember 2022-03-31 0001612042 ifrs-full:FinancialLiabilitiesAtFairValueMember ifrs-full:FinancialLiabilitiesAtAmortisedCostMember 2022-03-31 0001612042 asnd:ConvertibleSeniorNotesMember ifrs-full:FixedInterestRateMember 2022-03-31 0001612042 asnd:ConvertibleSeniorNotesMember 2022-03-31 0001612042 asnd:ConvertibleSeniorNotesMember asnd:AmericanDepositorySharesMember 2022-03-31 0001612042 asnd:AmericanDepositorySharesMember 2022-03-31 0001612042 asnd:RestrictedStockUnitsMember 2022-03-31 0001612042 ifrs-full:BottomOfRangeMember 2022-03-31 0001612042 ifrs-full:TopOfRangeMember 2022-03-31 0001612042 ifrs-full:DerivativesMember ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember 2022-03-31 0001612042 ifrs-full:DerivativesMember asnd:SharePriceMeasurementInputMember 2022-03-31 0001612042 asnd:ConvertibleSeniorNotesMember 2022-03-29 2022-03-29 0001612042 asnd:ConvertibleSeniorNotesMember ifrs-full:FixedInterestRateMember 2022-03-29 0001612042 asnd:ConvertibleSeniorNotesMember 2022-03-29 0001612042 asnd:VisenPharmaceuticalsMember 2021-01-01 2021-12-31 0001612042 ifrs-full:LiquidityRiskMember 2021-01-01 2021-12-31 0001612042 asnd:ConvertibleSeniorNotesMember asnd:AmericanDepositorySharesMember 2021-01-01 2021-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember 2021-12-31 0001612042 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember 2021-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:UsGovernmentBondsMember 2021-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:UsGovernmentBondsMember 2021-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:CommercialPapersMember 2021-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:CommercialPapersMember 2021-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:CorporateBondsMember 2021-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:CorporateBondsMember 2021-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:AgencyBondsMember 2021-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:AgencyBondsMember 2021-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember 2021-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember 2021-12-31 0001612042 ifrs-full:FixedInterestRateMember ifrs-full:FinancialAssetsAtAmortisedCostMember 2021-12-31 0001612042 ifrs-full:FixedInterestRateMember ifrs-full:FinancialAssetsAtFairValueMember 2021-12-31 0001612042 ifrs-full:FloatingInterestRateMember ifrs-full:FinancialAssetsAtAmortisedCostMember 2021-12-31 0001612042 ifrs-full:FloatingInterestRateMember ifrs-full:FinancialAssetsAtFairValueMember 2021-12-31 0001612042 asnd:ZeroCouponMember ifrs-full:FinancialAssetsAtAmortisedCostMember 2021-12-31 0001612042 asnd:ZeroCouponMember ifrs-full:FinancialAssetsAtFairValueMember 2021-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:HighGradeMember 2021-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:HighGradeMember 2021-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:UpperMediumGradeMember 2021-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:UpperMediumGradeMember 2021-12-31 0001612042 ifrs-full:FinancialAssetsAtAmortisedCostMember asnd:LowerMediumGradeMember 2021-12-31 0001612042 ifrs-full:FinancialAssetsAtFairValueMember asnd:LowerMediumGradeMember 2021-12-31 0001612042 ifrs-full:FinancialLiabilitiesAtFairValueMember ifrs-full:FinancialLiabilitiesAtAmortisedCostMember 2021-12-31 0001612042 asnd:AmericanDepositorySharesMember 2021-12-31 0001612042 country:DE asnd:OfficeFacilityMember 2022-01-31 2022-01-31 0001612042 asnd:ForeignCurrencyConversionOptionMember 2022-03-25 0001612042 country:DE asnd:OfficeFacilityMember 2022-01-31 0001612042 asnd:OfficeFacilityMember country:DE 2022-02-28 0001612042 asnd:Warrant1Member 2021-12-31 0001612042 ifrs-full:RetainedEarningsMember 2021-12-31 0001612042 ifrs-full:ReserveOfSharebasedPaymentsMember 2021-12-31 0001612042 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-12-31 0001612042 ifrs-full:TreasurySharesMember 2021-12-31 0001612042 ifrs-full:SharePremiumMember 2021-12-31 0001612042 ifrs-full:IssuedCapitalMember 2021-12-31 0001612042 ifrs-full:RetainedEarningsMember 2022-03-31 0001612042 ifrs-full:ReserveOfSharebasedPaymentsMember 2022-03-31 0001612042 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-03-31 0001612042 ifrs-full:TreasurySharesMember 2022-03-31 0001612042 ifrs-full:SharePremiumMember 2022-03-31 0001612042 ifrs-full:IssuedCapitalMember 2022-03-31 0001612042 asnd:RestrictedStockUnitsMember 2021-12-31 0001612042 ifrs-full:TreasurySharesMember 2020-12-31 0001612042 ifrs-full:RetainedEarningsMember 2020-12-31 0001612042 ifrs-full:ReserveOfSharebasedPaymentsMember 2020-12-31 0001612042 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-12-31 0001612042 ifrs-full:SharePremiumMember 2020-12-31 0001612042 ifrs-full:IssuedCapitalMember 2020-12-31 0001612042 ifrs-full:TreasurySharesMember 2021-03-31 0001612042 ifrs-full:RetainedEarningsMember 2021-03-31 0001612042 ifrs-full:ReserveOfSharebasedPaymentsMember 2021-03-31 0001612042 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-03-31 0001612042 ifrs-full:SharePremiumMember 2021-03-31 0001612042 ifrs-full:IssuedCapitalMember 2021-03-31 iso4217:EUR xbrli:shares iso4217:USD xbrli:pure utr:Month utr:Year asnd:Segment iso4217:DKK xbrli:shares iso4217:EUR xbrli:shares iso4217:USD xbrli:shares utr:Day asnd:Agreement
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO
SECTION 13a-16
OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of
May, 2022
Commission File Number:
001-36815
 
 
Ascendis Pharma A/S
(Exact Name of Registrant as Specified in Its Charter)
 
 
Tuborg Boulevard 12
DK-2900
Hellerup
Denmark
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form
20-F
or Form
40-F.
Form
20-F  ☒                Form
40-F  ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ☐
 
 
 

INCORPORATION BY REFERENCE
This report on Form
6-K
shall be deemed to be incorporated by reference into the registration statements on Form
S-8
(Registration Numbers
333-203040,
333-210810,
333-211512,
333-213412,
333-214843,
333-216883,
333-228576,
333-254101
and
333-261550)
and Form
F-3
(Registration Numbers
333-209336,
333-211511,
333-216882,
333-223134,
333-225284
and
333-256571)
of Ascendis Pharma A/S (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
 
 
Furnished as exhibits to this Report on Form
6-K
is information regarding the Company’s financial results for the fiscal quarter ended March 31, 2022.
Exhibits
 
Exhibit No.
  
Description
99.1
  
99.2
  
101.INS
  
XBRL Instance Document.
101.SCH
  
XBRL Taxonomy Extension Schema Document.
101.CAL
  
XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF
  
XBRL Taxonomy Extension Definition Linkbase Document.
101.IAB
  
XBRL Taxonomy Extension Labels Linkbase Document.
101.PRE
  
XBRL Taxonomy Extension Presentation Linkbase Document.
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
Ascendis Pharma A/S
Date: May 11, 2022
 
 
By:
 
/s/ Michael Wolff Jensen
 
 
 
Michael Wolff Jensen
 
 
 
Senior Vice President, Chief Legal Officer